Upcoming SlideShare
Loading in...5




26-28 MAY, 2013 - FIRST ANNUAL YOUTH ENTREPRENEURSHIP AND INNOVATORS CONFERENCE IN RUSSIA. STARTUP VILLAGE - one of the most ambitious start-up conferences in Russia, organized by Skolkovo in ...

26-28 MAY, 2013 - FIRST ANNUAL YOUTH ENTREPRENEURSHIP AND INNOVATORS CONFERENCE IN RUSSIA. STARTUP VILLAGE - one of the most ambitious start-up conferences in Russia, organized by Skolkovo in cooperation with partners. The conference is the first this year and will be held annually.

ONCOMETRIX is the first conference day's pitch session participant in the Life Science pavillion.



Total Views
Views on SlideShare
Embed Views



1 Embed 41

http://community.sk.ru 41


Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
Post Comment
Edit your comment

    ONCOMETRIX ONCOMETRIX Presentation Transcript

    • ONCOMETRIX: Breakthrough in prostate cancer diagnostics June 2013 office@camonx.com
    • Prostate Cancer – Most Common Cancer in Men More than 50% of men over 50 years old have prostatic symptoms Current prostate cancer diagnostics is not efficient: •  PSA – widely used primary diagnostic blood test •  70% false alarm •  25% false-negative (men with proven prostate cancer show normal PSA test result) •  BIOPSY– highly invasive final diagnostic work-up •  25% false negative results by multiple biopsy Non-invasive and cost-effective primary prostate cancer diagnostic method is needed BIOPSY
    • Market size 350 million men globally have prostatic symptoms Target market sectors: •  Precise diagnostic test for professional use (Point-Of-Care- Device): equal to PSA test market with 45 million tests yearly à 1.8 billion USD annually •  Primary test for home use (Over-The-Counter): 20% market penetration and 30 USD test kit price à 2.1 billion USD annually Potential market: 3.9 billion USD annually
    • Current Status A set of non-protein biomarkers was identified in prostate tissue samples from: •  35 healthy controls •  45 men with Benign Prostatic Hyperplasia •  60 men with Prostate Cancer Patent Application is filed on 45 biomarkers of prostate cancer (GB1307520.5) Further IP is to cover specific designs of diagnostic devices Work in progress to translate tissue results into prostatic and seminal fluids Optimising detection methods for selected biomarkers in prostatic and seminal fluids
    • New Method of Prostate Cancer Diagnostics We identified a group of novel non-protein biomarkers for prostate cancer in prostatic secretion and seminal fluid On the basis of the proprietary biomarkers team is developing 2 types of novel tests for prostate cancer: a.  Precise non-invasive diagnostic device for  professional use b.  Simple affordable prostate health test for home use (similar to a pregnancy test) Two types of novel tests are being developed: for professional and home use
    • Competitive Advantages Advantages of the Oncometrix tests: •  Measurement of several biomarkers at the same time increasing diagnostic accuracy significantly exceeding PSA •  Non-invasive •  Affordable •  Easy-to-use •  Use of a miniature portable device •  Immediate result High accuracy, easiness of use and cost-efficiency Marker 1 Marker 2 Tissue type: 1-Normal 2-BPH 3-PCa Concentration Tissue type
    • Competitive Analysis Promising performance to detect prostate cancer Prostate cancer diagnostic test PSA Oncometrix Accuracy 50 % 99 % Sensitivity 43-73 % 98 % Specificity 56-97 % 99 % Positive PredictiveValue* 17-30 % 74 % *- 65-69 years old
    • Stage 1: Proof of concept   • £300K           investment   • 20% of equity   • 18 months   • Selection of markers   • Detection methods optimization   • IP development and protection, patenting   Stage 2: Product development   • £3M             investment   • 24 months   • Device development and clinical trials   Stage 3: Commercialization •  £5 M investment •  36 months • Alternatively: self-funded scale-up • Business model: license sale and device manufacturing Exit   • Trade sale at £60-120M   • in year 6   • Alternatively: exit in year 4 (after regulatory approvals, Stage 2), at £30-50M   Project Timeline and Finance Total investments: £8.3 million Duration: 6 years Sales: £60-120 million
    • The Team Dedicated professionals from research and business areas, 8PhDs, 4 High-Tec entrepreneurs Prof. Vladimir Zaichick, FRSC, Chief Scientist over 50 years experience in medicinal physics and diagnostic method development.World leading authority in microelement composition of human tissues Dr Dmitry Soloviev, MRSC, Technology Adviser over 20 years experience in development and production of diagnostic radiopharmaceuticals. Cancer Research UK.   Dr Maxim Rossmann, Science Director over 10 years experience in development of Targeted Cancer Therapies and screening tests, enzymatic methods. Cambridge University.   Dr Mikhail Lomonosov, Managing Director over 12 years experience in Cancer Biomarkers and Molecular Therapies, Cambridge University.   Mrs Irina Soltamova Solovyev, Finance Director over 15 years experience in financial and business consulting and auditing. Dr Istvan Boros, MRSC, Patent Specialist 8 years experience as patent expert. Cambridge University Dr Pavel Shashkov, Business Adviser over 20 years experience in high-tech business development. Cambridge Nanolitic   Dr Dmitry Lebedev, MD, Urology Practitioner More than 10 years experience in clinical urology, participation in clinical trials.